Journal
ONCOTARGET
Volume 6, Issue 21, Pages 18250-18264Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.4213
Keywords
mastocytosis; KIT mutations; myeloproliferative disorder; alternative targets in mastocytosis; signaling pathways in mastocytosis
Categories
Funding
- National Institutes of Health [R01HL077177, R01HL081111, R01CA173852, R01CA134777]
- Riley Children's Foundation
- American Cancer Society Post Doctoral Fellow [PF-13-065-01]
Ask authors/readers for more resources
Although more than 90% systemic mastocytosis (SM) patients express gain of function mutations in the KIT receptor, recent next generation sequencing has revealed the presence of several additional genetic and epigenetic mutations in a subset of these patients, which confer poor prognosis and inferior overall survival. A clear understanding of how genetic and epigenetic mutations cooperate in regulating the tremendous heterogeneity observed in these patients will be essential for designing effective treatment strategies for this complex disease. In this review, we describe the clinical heterogeneity observed in patients with mastocytosis, the nature of relatively novel mutations identified in these patients, therapeutic strategies to target molecules downstream from activating KIT receptor and finally we speculate on potential novel strategies to interfere with the function of not only the oncogenic KIT receptor but also epigenetic mutations seen in these patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available